Fig. 7

Dasatinib significantly suppresses LPS-induced proinflammatory cytokine COX-2 and iNOS mRNA levels in primary astrocytes. a Primary astrocyte cells were treated with vehicle (1% DMSO) or dasatinib (100, 250, 500, 750, or 1000 nM) for 6 h, and MTT assays were conducted under low-glucose conditions (100 nM, n = 6; 250 nM, n = 6; 500 nM, n = 6; 750 nM, n = 6; or 1000 nM, n = 6). b Primary astrocyte cells were treated with vehicle (1% DMSO) or dasatinib (100, 250, 500, 750, or 1000 nM) for 6 h, and BrdU proliferation assays were conducted under low-glucose conditions (100 nM, n = 6; 250 nM, n = 6; 500 nM, n = 6; 750 nM, n = 6; or 1000 nM, n = 6). c Primary astrocytes were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (200 ng/ml) or PBS for 6 h, and MTT assays were performed under low-glucose conditions (con, n = 6; LPS, n = 6; dasatinib+LPS, n = 6). d Primary astrocytes were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (200 ng/ml) or PBS for 6 h, and BrdU proliferation assays were performed under low-glucose conditions (con, n = 6; LPS, n = 6; dasatinib+LPS, n = 6). e Mouse primary astrocytes were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, and proinflammatory cytokine levels were measured by RT-PCR under low-glucose conditions. f–j Quantification of the data in e (COX2, IL-6, IL-1β, iNOS, and TNF-alpha: con, n = 8; LPS, n = 8; dasatinib+LPS, n = 8). k Mouse primary astrocytes were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, and proinflammatory cytokine levels were measured by RT-PCR under high-glucose conditions. l–p Quantification of the data in k (COX2, IL-6, IL-1β, iNOS, and TNF-alpha: con, n = 10; LPS, n = 10; dasatinib+LPS, n = 10). q Rat primary astrocytes were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, and proinflammatory cytokine levels were measured by RT-PCR under high-glucose conditions. r–v Quantification of the data in q (COX2, IL-6, IL-1β, iNOS, and TNF-alpha: con, n = 20; LPS, n = 20; dasatinib+LPS, n = 20). Two-tailed t tests (a, b) and one-way ANOVA with Tukey’s post hoc test (c–v) were used to analyze significant differences. *p < 0.05, **p < 0.01, ***p < 0.001